All studies · Mortality · Serious outcomes · Recovery · RCTs · RCT mortality · Peer-reviewed · All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−22%

Mortality (1)−22%

RCTs (1)−22%

Late (1)−22%

00.511.5+

← Lufotrelvir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Lufotrelvir COVID-19 studies

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26

Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.68

All studies−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 mortality results

c19early.org

November 2026

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.989/326/26

Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.68

All studies−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 serious outcomes

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26

Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.68

All studies−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 recovery results

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Grandits (DB RCT)44%0.56 · 0.29–1.10no disch.9/3213/26

Late treatment44%0.56 · 0.29–1.109/3213/2644% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.094

All studies44%0.56 · 0.29–1.109/3213/2644% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.09400.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 Randomized Controlled Trials

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26

Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.68

All studies−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 RCT mortality results

c19early.org

November 2026

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.989/326/26

Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.68

All studies−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 peer reviewed studies

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26

Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.68

All studies−22%1.22 · 0.50–2.989/326/2622% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Lufotrelvir COVID-19 outcomes

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26 Grandits (DB RCT)44%0.56 · 0.29–1.10no disch.9/3213/26

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Lufotrelvir
reduces riskLufotrelvir
increases risk →

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Lufotrelvir: meta-analysis of COVID-19 studies

Lufotrelvir COVID-19 studies

Lufotrelvir COVID-19 mortality results

Lufotrelvir COVID-19 serious outcomes

Lufotrelvir COVID-19 recovery results

Lufotrelvir COVID-19 Randomized Controlled Trials

Lufotrelvir COVID-19 RCT mortality results

Lufotrelvir COVID-19 peer reviewed studies

Lufotrelvir COVID-19 outcomes